Effects of blood pressure and antihypertensive drugs on osteoarthritis: a mendelian randomized study
Authors:
Open Access
- 21 August 2023
- journal article
- research article
- Published by Springer Nature in Aging Clinical and Experimental Research
- Vol. 35 (11) , 2437-2444
Abstract
Background: Previous studies have suggested that antihypertensive drugs may play a role in the treatment of osteoarthritis, but these studies may be limited by confounding factors and lead to biased results. Therefore, we conducted a Mendelian randomization study to investigate the effects of blood pressure and antihypertensive drugs on osteoarthritis. Methods: We used published large-scale genome-wide association data and applied univariate and multivariate Mendelian randomization methods. The main analysis model was inverse variance weighting, and the reliability of the results was tested using MR-Egger intercept analysis, Cochran's Q test, and leave-one-out analysis. We comprehensively evaluated the relationship between systolic blood pressure, diastolic blood pressure, 12 antihypertensive drugs, and osteoarthritis. We also conducted verification in the independent queue of UK Biobank and built a simple linear regression model to obtain an independent comparison. Results: We found no evidence that systolic and diastolic blood pressure significantly affected osteoarthritis. However, among antihypertensive drugs, we observed a significant positive correlation between potassium-preserving diuretics and aldosterone antagonists and all osteoarthritis (OR: 0.560, 95% CI 0.406–0.772, P = 0.0004). Sensitivity analysis showed no horizontal pleiotropy or heterogeneity, and the leave-one-out analysis demonstrated the reliability of the results. This result was replicated with nominally statistical significance in the validation cohort and exhibited significant correlation in the linear regression analysis. Conclusions: Our study suggested that controlling the protein targets of potassium-sparing diuretics and aldosterone antagonists may have beneficial results for osteoarthritis. These findings provide valuable medication strategies for the control of hypertension in patients with osteoarthritis.Keywords
Funding Information
- Jilin Provincial Scientific and Technological Development Program (20210303004SF)
- Natural Science Foundation of Jilin Province (YDZJ202201ZYTS216)
This publication has 27 references indexed in Scilit:
- Association between hypertension and risk of knee osteoarthritisMedicine, 2017
- Association of Beta‐Blocker Use With Less Prevalent Joint Pain and Lower Opioid Requirement in People With OsteoarthritisArthritis Care & Research, 2016
- Exploratory analysis of osteoarthritis progression among medication users: data from the Osteoarthritis InitiativeTherapeutic Advances in Musculoskeletal Disease, 2016
- Spironolactone for People Age 70 Years and Older With Osteoarthritic Knee Pain: A Proof‐of‐Concept TrialArthritis Care & Research, 2016
- Low-dose Spironolactone: Treatment for Osteoarthritis-related Knee Effusion. A Prospective Clinical and Sonographic-based StudyThe Journal of Rheumatology, 2016
- Differences in the Antinociceptive Effects and Binding Properties of Propranolol and Bupranolol EnantiomersThe Journal of Pain, 2015
- Association between Hypertension and the Prevalence of Low Back Pain and Osteoarthritis in Koreans: A Cross-Sectional StudyPLOS ONE, 2015
- Spironolactone inhibits production of proinflammatory cytokines, including tumour necrosis factor-α and interferon-γ, and has potential in the treatment of arthritisClinical and Experimental Immunology, 2003
- 10 Economics of osteoarthritis: a global perspectiveBailliere's Clinical Rheumatology, 1997
- Development of criteria for the classification and reporting of osteoarthritis: Classification of osteoarthritis of the kneeArthritis & Rheumatism, 1986